

[Handwritten signature]
19. The method of claim 10, wherein the inhibitor is an indirect MMP inhibitor.

REMARKS

Claims 18 and 19 have been amended to properly depend from method claim 10, the "0" having been accidentally left off of the reference dependency.

Applicants appreciate the Examiner's attention to this application and regret the inconvenience of having presented additional claims requiring restriction, so this response is promptly filed.

Respectfully submitted,

OFFICIAL

[Handwritten signature: Bradley N. Ruben]
Bradley N. Ruben
Reg. No. 32,058
Hopgood, Calimafde,
Judlowe & Mondolino L.L.P.
60 East 42nd Street
New York, NY 10165
212-551-5000 ext. 4081
fax 212-949-2795

CERTIFICATE OF MAILING OR TRANSMISSION – 37 CFR 1.8

I hereby certify that I have a reasonable basis that this paper, along with any referred to above, (i) are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, or (ii) are being transmitted to the U.S. Patent & Trademark Office in accordance with 37 CFR § 1.6(d).

DATE: 14 Nov. 2001

NAME: Brad Ruben

SIGNATURE: *[Handwritten signature: Brad Ruben]*

Dated: 14 November 2001

APPENDIX SHOWING MARK-UPS OF AMENDMENTS

18. (Amended.) The method of claim 10, wherein the inhibitor is a direct MMP inhibitor.

19. (Amended.) The method of claim 10, wherein the inhibitor is an indirect MMP inhibitor.